Coronary physiology and percutaneous intervention managed with gadolinium road mapping and intravascular ultrasound in hyperthyroidism

Peter Tajti1,2*, Mohamed Ayoub1*, Thomas Nuehrenberg1, Kambis Mashayekhi1

1Department of Interventional Cardiology, Cardiology and Angiology II, University Heart Center Freiburg — Bad Krozingen, Germany
2Gottsegen György Hungarian Institute of Cardiology, Budapest, Hungary

Introduction

The incidence of iodine-induced thyrotoxicosis after the administration of iodinated contrast agent remains low in various patient cohorts (0.2% to 1.9% [1, 2]). In patients with coexisting subclinical hyperthyroidism and ischemic heart disease, however, contrast administration may provoke or worsen its clinical condition requiring additional endocrinology treatment and clinical follow-up after the initial coronary angiography (CAG) or percutaneous coronary intervention (PCI) [3]. Alternative contrast agents — such as gadolinium — replacing iodinated contrast media during coronary angiography have been introduced previously in small cohorts and case reports to avoid nephrotoxicity [4, 5], contrast allergy [6], or iodinated-contrast-induced thrombocytopenia [7]. The present study, describes a case using a low amount of gadolinium for coronary anatomy reconstruction assisting the coronary physiology and imaging guided PCI in an elderly patient with acute coronary syndrome (ACS) who was simultaneously diagnosed with hyperthyroidism.

Case report

An 85-year-old-man, with a history of coronary artery disease (CAD), was referred to the documented center with severe ongoing chest pain and progressive dyspnea. The patient had a prior PCI of the right coronary artery and distal left circumflex artery (LCX) performed 1 year prior to the current admission to hospital. Additionally, the patient had severe peripheral artery disease and had undergone multiple prior percutaneous transluminal angioplasty of the limbs. Relevant coronary risk factors included hypertension, hypercholesterinemia and positive family history of CAD. The patient was hemodynamically stable, and on physical examination no relevant abnormalities were detected. Initial laboratory testing revealed an elevated level of high sensitive troponin T and a normal level of creatine kinase (CK), and creatine kinase myocardial band (CK-MB). An electrocardiogram showed no relevant ST segment changes, and transthoracic echocardiography showed normal biventricular function (left ventricular ejection fraction of 55%) without significant valve disease. The estimated glomerular filtration rate was 74 mL/min/1.73 m². Additionally, thyroid stimulating hormone was suppressed, 0.11 µIU/L (normal range [NR] 0.27–4.2 µIU/L), whereas T₃ (4.2 pmol/L [NR 3.1–6.8 pmol/L]) and T₄ was normal (16.7 pmol/L [NR 12–22 pmol/L]). Due to the possibly underlying subclinical hyperthyroidism, an endocrinological consultation took place which revealed the first diagnosis of an ongoing thyroid autonomy.

A decision was made to proceed with invasive CAG within 72 hours due to intermediate risk, using low-dose gadolinium for anatomy road mapping.
According to a previously reported risk of cardiac arrhythmia and potential hemodynamic instability [8], 5 mg of metoprolol intravenously (relative beta-1 selectivity) was administered, defibrillator paddles were applied, hemodynamics were continuously measured and 1–2 cc first time injections before angiography of the left and right coronaries were administered (Fig. 1A, B). Coronary physiology assessment of fractional flow reserve (FFR) (Comet pressure wire, Boston Scientific, Natick, Massachusetts, USA) was performed. At maximum hyperemia, FFR of the left anterior descending artery (LAD) was positive (0.77), whereas LCX remained functionally insignificant (0.89). Thereafter proceeding with PCI, exchanging for regular workhorse wire (Sion Blue [Asahii Intecc, Nagoya, Japan]) and evaluating the plaque burden, vessel diameter and lesion length (Fig. 1C) with intravascular ultrasound (IVUS [Eagle Eye, Philips Volcano, Amsterdam, Netherlands]). Two drug eluting stents were implanted (2.5 × 12 mm, 2.75 × 38 mm) in the middle and proximal LAD segments. After post-dilation optimal stent expansion was confirmed with control IVUS (Fig. 2). Total procedure and fluoroscopy times were 55 and 10 minutes, respectively. 35 mL of gadolinium was used overall. The patient was discharged on dual antiplatelet therapy on the 4th day post-PCI. Endocrinology control was scheduled to evaluate the thyroid autonomy 2 weeks post-PCI, and thiamazole was added to his therapy at discharge.

**Discussion**

This report illustrates the concept of using gadolinium to map the coronary anatomy in patients with absolute contraindication of using conventional iodinated contrast agents, that can assist coronary physiology and IVUS for percutaneous management of CAD without any iodinated contrast use.

The incidence of iodine-induced thyrotoxicosis after administration of iodinated contrast agent remains low, which mostly results in subclinical hyperthyroidism in euthyroid patients regardless [1, 2]. Nevertheless, coexisting subclinical hyperthyroidism and ischemic heart disease combined with iodinate contrast load after CAG has a significant impact on worsening its clinical conditions that may require further treatment, clinical follow-up or even re-hospitalization after 1 year of CAG/PCI [3]. Bonelli et al. [3] analyzed an 810
patient cohort without known thyroid diseases who had undergone elective CAG. At baseline, 7.2% of the patients had hyperthyroidism, that increased to 10% after CAG. Independent predictors of hyperthyroidism development were baseline free T₄ levels, thyroid nodules, age > 60, male gender, and positive family history of thyroid diseases. Despite endocrinology follow up and therapy optimization, 4.2% at 3 months, and 2.5% at one year still had hyperthyroidism [3]. Additionally, in elderly patients, the risk of thyrotoxicosis after CAG with underlying thyroid disease is increased [9], and can be potentially life threatening, that may lead to cardiac tachyarrhythmias, heart failure, pulmonary arterial hypertension, pulmonary embolism, and cardiomyopathy.

Current guidelines propose early decision making on timing of angiography and possible intervention, especially in high-risk patient subgroups (elevated cardiac biomarkers at baseline, coexisting diabetes mellitus, Global Registry of Acute Coronary Events Risk Score [GRACE score > 140], age of 75 ≤ years) with the ultimate goals of reducing length of hospital stay, refractory ischemia and mortality. In the present report, the patient’s GRACE score was 137, thus current ESC/EACTS guidelines indicates invasive treatment in < 72 hours (Class I, Level A) [10]. The use of coronary physiology (such as FFR or instant wave-free ratio) has been established as a feasible and effective option for culprit lesion identification in ACS patients with multivessel disease, nevertheless its prognostic value remains limited [10]. Moreover, identification of the culprit lesion remains challenging in a non-negligible number of cases with non-ST elevation ACS, that may require additional tools — such as intravascular imaging — which may further assist clinical decision making. Coronary physiology combined with intravascular imaging (IVUS in the current report) provides a meticulous assessment of plaque instability and flow limitation, that has also confirmed the need for intervention in the aforementioned clinical scenario where conventional iodinated contrast use was not amenable.

Zero contrast and ultra-low contrast use [11] during PCIs treatment of complex CAD (such as chronic total occlusions) has been previously reported. The latter studies, however, reported...
contrast administration (zero contrast PCI was defined < 15 mL use of contrast medium), or recent diagnostic angiography was available before PCI that served as a road map for these technically challenging cases.

The use of gadolinium, as an alternative option for replacing iodinated contrast media for coronary angiography has been previously introduced [8], however its use has been limited due to (a) lower image quality, (b) potential adverse events of ventricular tachycardia/fibrillation or hemodynamic instability, and (c) its relatively high cost. The combination of IVUS and gadolinium has been reported to overcome an adverse reaction of iodinated contrast induced thrombocytopenia [7].

Applying gadolinium only for coronary road mapping (limiting its use only for the initial and final angiography) in combination with coronary physiology and IVUS is a potential option to guide complex coronary interventions with the benefit of fully avoiding using low osmolality iodinated contrast agents and hindering nephrotoxicity, adverse allergic reactions or thyrotoxicosis post-PCI. Before gadolinium injection, precautionary steps are mandatory to avoid adverse cardiac events. Herein, protocol included the following steps: (a) administration of intravenous beta-blocker, (b) applying defibrillator paddles, (c) monitoring arterial pressure, (d) avoiding pressure dampening of guiding catheters (use of guiding catheters with side holes however, could further reduce image quality), (e) and adding slow and low amounts of test injections.

Conclusions

This report demonstrates the feasibility of a concept combining gadolinium, IVUS, and coronary physiology to treat patients with CAD and severe coexisting comorbidities that can be aggravated by iodinated contrast media.

Conflict of interest: Kambis Mashayekhi, MD: honoraria/consulting fees from Ashai Intecc, Boston, Medtronic, Teleflex, Cardinal Health, Abbott, Biotronik, Terumo, AstraZeneca, Daiichi Sankyo; Remaining authors: nothing to disclose.

References